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background: During progression of cardiac injury, macrophages are actively involved in inflammatory responses. Previous study showed 
that 5-azacytidine (5AZ), an inhibitor of DNA methylation, ameliorated cardiac injury by modulating macrophage phenotypes. In this study, we 
investigated the underlying mechanism of 5AZ in macrophages.
Methods: A mouse macrophage cell line RAW264.7 was stimulated with lipopolysaccharide (LPS) with or without 5AZ. Nitric oxide was quantified 
by Griess’s method. Expressions of inducible nitric oxide synthase (iNOS), interferon regulatory factor 1 (IRF-1) and Elk3 were determined by Western 
blot. For animal study, myocardial infarction (MI) was induced by ligation of left coronary artery in mice, and saline or 5AZ was injected (5 mg/kg/d, 
intraperitoneal injection) every two other day. Cardiac fibrosis was evaluated by Masson’s trichrome stain was performed and cardiac function was 
by echocardiography 2 weeks after MI.
results: LPS-induced nitric oxide formation was reduced by 5AZ treatment in RAW264.7 cells (19.37 ± 0.70 pg/mL vs. 10.43 ± 0.90 pg/mL, p 
< 0.05). LPS-induced iNOS expression was blocked by 5AZ treatment. Next, the effect of 5AZ on IRF1 and Elk3, regulators of iNOS, were examined. 
IRF-1 was dramatically increased by LPS to peak at 4 hr and then rapidly degraded. In the presence of MG132, a proteasome inhibitor, IRF-1 protein 
sustained maximal level. On the other hand, IRF-1 protein was significantly highly maintained by 5AZ treatment. Elk3, an endogenous iNOS inhibitor, 
was upregulated by 5AZ treatment. In animal study, cardiac function was significantly preserved by 5AZ administration. There were significant 
improvements in ejection fraction (53.25 ± 2.55% vs. 62.50 ± 7.2%, p < 0.05) and cardiac fibrosis (28.85 ± 5.44% vs. 16.57 ± 6.30%, p < 0.05). 
Collectively, 5AZ inhibited iNOS induction by modulation of IRF-1 and Elk3 in the activated macrophages to preserved cardiac function and fibrosis 
after MI.
conclusions: 5AZ protected post-MI injury by regulation of IRF-1 kinetics and induction of Elk3 to modulate macrophages in infarcted 
myocardium. This study suggested 5AZ as a novel therapeutic intervention for cardiac repair. 
